Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 15, Issue 4, 2013, Pages

  Boggs, Douglas L ^a,b   Ranganathan, Mohini ^a,b,c   Boggs, Angela A ^a   Bihday, Christine M ^a   Peluse, Barbara E ^a   D'Souza, Deepak C ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; TAMOXIFEN;

ADULT; AFRICAN AMERICAN; BREAST TENDERNESS; CASE REPORT; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DSM-IV; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INDIAN; LETTER; MALE; PHYSICAL EXAMINATION; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SUICIDE ATTEMPT; TOBACCO DEPENDENCE;

EID: 84884233340     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13l01519     Document Type: Letter

References (7)

1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. PubMed doi:10.2165/00003495-200464200-00003 Show Abstract
2. Shim J-C, Shin J-GK, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-1410. PubMed doi:10.1176/appi.ajp.2007.06071075 Show Abstract
3. Lee B-H, Kim Y-K, Park S-H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714-717. PubMed doi:10.1016/j.pnpbp.2006.02.001 Show Abstract
4. Yasui-Furukori N, Furukori H, Sugawara N, et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596-599. PubMed doi:10.1097/JCP.0b013e3181ee832d Show Abstract
5. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348-1357. PubMed doi:10.4088/JCP.09m05154yel Show Abstract
6. van Kooten M, Arends J, Cohen D. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol. 2011;31(1):126-128. PubMed doi:10.1097/JCP.0b013e318205e1aa Show Abstract
7. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61. PubMed doi:10.1097/00004714-199902000-00011 Show Abstract